Skip to main content
. 2019 Jul 26;78(10):1320–1332. doi: 10.1136/annrheumdis-2019-215163

Figure 1.

Figure 1

Patient disposition. *The number of patients who were allocated at randomisation to either peficitinib 100 mg or peficitinib 150 mg starting from week 12. †Discontinuation up to week 12: discontinued at any time from date of randomisation through day 85. ‡Discontinuation for overall period: discontinued at any time from first dose of study drug through the last dose day for overall period.